Targeting a specific enzyme to improve cancer treatment outcomes in breast cancer and melanoma

Targeting ATP-citrate lyase (ACLY) to overcome therapy resistance in breast cancer and melanoma

NIH-funded research Pace University New York · NIH-10580197

This study is looking at how a specific enzyme called ACLY affects breast cancer and melanoma, and it aims to see if blocking this enzyme can help make current treatments work better for patients who have developed resistance to them.

Quick facts

Grant typeR15 grant
Study typeNIH-funded research
Funding institutionPace University New York NIH-funded
Lab location1 site (New York, United States)
Project IDNIH-10580197 on NIH RePORTER

What this research studies

This research investigates the role of ATP-citrate lyase (ACLY) in breast cancer and melanoma, focusing on how cancer cells develop resistance to existing therapies. By inhibiting ACLY, which is linked to cancer cell metabolism and growth, the study aims to enhance the effectiveness of current treatments. The approach involves combining ACLY inhibitors with established therapies to potentially overcome resistance mechanisms that cancer cells use to evade treatment. Patients may be monitored for changes in tumor response and overall health as part of this innovative strategy.

Who could benefit from this research

Good fit: Ideal candidates for this research are patients with breast cancer or melanoma who are experiencing treatment resistance.

Not a fit: Patients with early-stage cancer who have not yet undergone treatment may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to more effective treatment options for patients with breast cancer and melanoma who have developed resistance to current therapies.

How similar studies have performed: Other research has shown promising results in targeting metabolic pathways in cancer, suggesting that this approach could be effective.

Where this research is happening

New York, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Anti-Cancer AgentsCancer DrugNeoplastic Disease Chemotherapeutic Agents
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.